Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
Treatment outcomes with chemo-immunotherapy in BV-MCL patients are poor, especially among TP53-mutated patients. Recent findings describing positive outcomes with novel BTKi-based therapies are encouraging and should be considered in this high-risk population.
Authors
- Elizabeth Brém (ORCID: https://orcid.org/0000-0002-3265-9841)
- Shawn P. Griffin (ORCID: https://orcid.org/0000-0002-3818-2490)
- Jean Doh (ORCID: https://orcid.org/0000-0003-2737-5243)
- Piyanuch Kongtim (ORCID: https://orcid.org/0000-0003-2130-7645)
- Stefan O. Ciurea (ORCID: https://orcid.org/0000-0001-8597-3271)
- Benjamin J. Lee (ORCID: https://orcid.org/0000-0002-1678-1345)
- Jenny Liu
Institutions
- University of California, Irvine (US)
- UC Irvine Health (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70310
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00